Article thumbnail

Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials

By Wen-cong Li, Mao-rong Wang, Ling-bo Kong, Wei-guang Ren, Yu-guo Zhang and Yue-min Nan
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3128052
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2009). A prospective, randomized study of efficacy and safety of peginterferon alfa-2a versus adefovir dipivoxil in treating lamivudine-resistant HBeAg-positive CHB. J Hepatol
  2. (2009). A randomized controlled trail of pegylated interferon-alpha 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antiviral Therapy
  3. (2008). Archimandritis AJ: Current treatment indications and strategies in chronic hepatitis B virus infection.
  4. (2007). Asselah T: Treatment of chronic hepatitis B with the combination of pegylated interferon with lamivudine. Hepatology Research
  5. (2006). BEHoLD AI463027 Study Group: Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.
  6. (2006). BP: Efficacy and safety of peginterferon alfa-2a treatment in patients with HBeAg-positive chronic hepatitis B. Chinese J Exp Clin Virol
  7. (2009). Brett-Smith H: Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy.
  8. (2009). Chu CM: Hepatitis B virus infection. Lancet
  9. (2009). Comparison of peginterferon alfa-2a versus entecavir in patients with HBeAg-positive chronic hepatitis B with mildly elevated alanine aminotransferase levels.
  10. (2005). Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone. Ann Intern Med
  11. (2009). European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of chronic hepatitis
  12. (2002). F: Outcome of anti-HBe positive chronic hepatitis B in alphainterferon treated and untreated patients: a long term cohort study.
  13. (2002). Geneva, Switzerland: consensus statement (long version).
  14. (2008). GKK: Virological and biochemical response in patients with HBeAg negative chronic hepatitis B treated with peginterferon alfa-2a (40 kd) with or without lamivudine: results of 4-year follow-up.
  15. (2005). Group: Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
  16. (1996). Häussinger D: Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B.
  17. (2009). HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon. Liver International
  18. (2005). HBV 99-01 Study Group; Rotterdam Foundation for Liver Research: Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet
  19. (1996). HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials
  20. (2010). HL: Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology
  21. (2008). HL: Sustained HBeAg and HBsAg Loss after Longterm Follow-up of HBeAg-Positive Patients Treated With Peginterferon α-2b. Gastroenterology
  22. (2010). HQ: Evaluation of Efficacy of Peginterferonα-2a Therapy in patients with HBeAg Positive Chronic Hepatitis B.
  23. (2009). Increasing rates of HBsAg clearance and seroconversion in patients with HBeAg-negative disease treated with peginterferon alfa-2a ± lamivudine: results of 5-year posttreatment follow up.
  24. (2007). Investigation of PEG-IFNα-2a treatment of chronic hepatitis B patients who failed to lamivudine therapy. J Cl in Hepatol
  25. (2006). JF: Pegylated interferon in treating HBeAg negative chronic hepatitis B patients.
  26. (2007). Liaw YF: Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma.
  27. (2002). Liaw YF: Longterm outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology
  28. (2003). Long-term suppression of hepatitis B e antigennegative chronic hepatitis B by 24-month interferon therapy. Hepatology
  29. (2009). McMahon BJ: Chronic hepatitis B: update 2009. Hepatology
  30. (2004). McMahon BJ: Chronic hepatitis B: update of recommendations. Hepatology
  31. (2007). McMahon BJ: Chronic hepatitis B. Hepatology
  32. (2007). Okten A: Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E AntigenNegative Chronic Hepatitis B. Antimicrob Agents Chemother
  33. (2004). Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group: Peginterferon alfa-2a alone, Lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.
  34. (2005). Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group: Peginterferon alfa-2a, Lamivudine, and the combination for HBeAg-positive chronic hepatitis B.
  35. (2008). Perrillo R: Hepatitis B: Reflections on the current approach to antiviral therapy.
  36. (2010). RR: Hepatitis B: Diagnosis and Treatment. Am Fam Physician
  37. (1998). Schalm SW: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis.
  38. (2005). Sung JJ: Long-Term Follow-Up of Peginterferon and Lamivudine Combination Treatment in HBeAg-Positive Chronic Hepatitis B. Hepatology
  39. (2008). Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
  40. The Primary Clinical Study of Peginterferon
  41. (2001). Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology
  42. (2006). Yang YJ: Pegylated interferon alpha 2a in treating chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi
  43. (2010). ZL: A pilot study of peginterferon alfa-2a combined with short-term lamivudine therapy in HBeAg-positive chronic hepatitis B patients. Zhonghua Gan Zang Bing Za Zhi